This week's View offers key points to remember from an opinion article on the current diagnostic criteria and differential diagnosis of arrhythmogenic right ventricular cardiomyopathy and a consensus statement on the diagnosis of heart failure (HF) with preserved ejection fraction (EF) and also addresses how sacubitril/valsartan impacts certain biomarker levels compared with enalapril in patients with HF and reduced EF.

Subscribe on iTunes | Subscribe on Google Play

Keywords: EaglesEyeView, Amyloidosis, Arrhythmias, Cardiac, Arrhythmogenic Right Ventricular Dysplasia, Atrial Fibrillation, Biomarkers, Blood Pressure, Brugada Syndrome, Cardiac Catheterization, Cardiomyopathies, Cardiomyopathy, Hypertrophic, Diagnosis, Differential, Diagnostic Imaging, Diastole, Echocardiography, Echocardiography, Stress, Electrocardiography, Enalapril, Genetic Testing, Guanosine Monophosphate, Heart Defects, Congenital, Heart Failure, Hypertrophy, Hypertrophy, Left Ventricular, Magnetic Resonance Imaging, Mutation, Myocarditis, Natriuretic Peptides, Natriuretic Peptide, Brain, Outcome Assessment, Health Care, Peptide Fragments, Pulmonary Wedge Pressure, Sarcoidosis, Pediatrics, Stroke Volume, Tachycardia, Ventricular, Tricuspid Valve Insufficiency, Troponin, Troponin T, Anticoagulants

< Back to Listings